journal article·2024-10Open access

Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

Fuxin Xue, Xitong Ren, Chaoying Kong, Jianfeng Wang, Linlin Liu, Junli Hu, Na Shen, Zhaohui Tang

Abstract

Immune checkpoint blockade (ICB) therapy, particularly PD1/PDL1 inhibition, has demonstrated success in bolstering durable responses in patients. However, the response rate remains below 30 %. In this study, we developed a polymeric bispecific antibody (BsAb) targeting PD1/PDL1 to enhance ICB therapy. Specifically, poly(L-glutamic acid) (PGLU) was conjugated with a double cyclic Fc binding peptide, Fc-III-4C, through condensation reactions between the -COOH group of PGLU and the -NH2 group of Fc-III-4C. This conjugate was then mixed with αPD1 and αPDL1 monoclonal antibodies (mAbs) in an aqueous solution. Mechanistically, the PD1/PDL1 BsAb (BsAbαPD1+αPDL1) acts as a bridge between tumor cells and CD8+ T cells, continuously activating CD8+ T cells to a greater extent. This leads to significantly suppressed tumor growth and prolonged survival in a mouse model of colon cancer compared to treatment with either a single mAb or a mixture of free mAbs. The tumor suppression rate achieved by the BsAbαPD1+αPDL1 was 90.1 %, with a corresponding survival rate of 83.3 % after 48 days. Thus, this study underscores the effectiveness of the BsAbαPD1+αPDL1 as a synchronizing T cell engager and dual ICBs, offering theoretical guidance for clinical ICB therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Cancer Immunotherapy and Biomarkers · CAR-T cell therapy research · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (46)

Show source-provided references
1. Big opportunities for small molecules in immuno-oncology10.1038/nrd4596 ↗
2. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications10.1038/s41423-020-0488-6 ↗
3. A decade of immune-checkpoint inhibitors in cancer therapy10.1038/s41467-020-17670-y ↗
4. Beyond immune checkpoint blockade: emerging immunological strategies10.1038/s41573-021-00155-y ↗
5. Revisiting the PD-1 pathway
6. Organic-solvent-free “lego-like” modular preparation of fab-nondestructive antibody-drug conjugates with ultra-high drug-to-antibody ratio
7. Pd-l1 expression in colon cancer and its relationship with clinical prognosis
8. PD-L1 promotes tumor growth and progression by activating wip and β-catenin signaling pathways and predicts poor prognosis in lung cancer10.1038/s41419-020-2701-z ↗
9. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway10.1038/s41401-020-0366-x ↗
10. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth10.1016/j.cell.2015.08.052 ↗
11. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer10.1056/NEJMoa1801005 ↗
12. Phase i study of single-agent anti-programmed death-1 (mdx-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates10.1200/JCO.2009.26.7609 ↗
13. Safety, activity, and immune correlates of anti-pd-1 antibody in cancer10.1056/NEJMoa1200690 ↗
14. Azide-masked resiquimod activated by hypoxia for selective tumor therapy10.1002/adma.202207733 ↗
15. Pembrolizumab versus docetaxel for previously treated, pd-l1-positive, advanced non-small-cell lung cancer (keynote-010): a randomised controlled trial10.1016/S0140-6736(15)01281-7 ↗
16. Pembrolizumab versus chemotherapy for pd-l1-positive non-small-cell lung cancer10.1056/NEJMoa1606774 ↗
17. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer10.1056/NEJMoa1504627 ↗
18. T cell-engaging therapies — bites and beyond10.1038/s41571-020-0347-5 ↗
19. Nanobody-based bispecific t-cell engager (nb-bite): a new platform for enhanced t-cell immunotherapy
20. Blinatumomab: a cd19/cd3 bispecific t cell engager (bite) with unique anti-tumor efficacy10.3109/10428194.2016.1161185 ↗
21. Tebentafusp, a tcr/anti-cd3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma10.1158/1078-0432.CCR-20-1247 ↗
22. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study10.1016/S1470-2045(22)00335-7 ↗
23. Teclistamab, a b-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (majestec-1): a multicentre, open-label, single-arm, phase 1 study10.1016/S0140-6736(21)01338-6 ↗
24. Emicizumab, a bispecific antibody to factors ix/ixa and x/xa, does not interfere with antithrombin or tfpi activity in vitro10.1055/s-0038-1636538 ↗
25. A high throughput bispecific antibody discovery pipeline
26. Bispecific antibodies: a mechanistic review of the pipeline10.1038/s41573-019-0028-1 ↗
27. Development of the double cyclic peptide ligand for antibody purification and protein detection10.1021/acs.bioconjchem.6b00170 ↗
28. An fc binding peptide-based facile and versatile build platform for multispecific antibodies10.1021/acs.nanolett.3c00071 ↗
29. Characterization of the Fc-III-4C-based recombinant protein expression system by using carbonic anhydrase as the model protein10.1016/j.pep.2020.105761 ↗
30. Fc-binding antibody-recruiting molecules exploit endogenous antibodies for anti-tumor immune responses10.1039/D0SC00017E ↗
31. Cisplatin loaded poly(l-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for potential cancer therapy: preparation, in vitro and in vivo evaluation10.1166/jbn.2016.2152 ↗
32. Glucose-sensitive polymer nanoparticles for self-regulated drug delivery10.1039/C6CC02202B ↗
33. Poly(l-glutamic acid)--anticancer drug conjugates10.1016/S0169-409X(02)00045-5 ↗
34. Immune checkpoint inhibitors: recent progress and potential biomarkers10.1038/s12276-018-0191-1 ↗
35. Erratum: molecular mechanisms of t cell co-stimulation and co-inhibition
36. Cancer immunotherapy comes of age10.1038/nature10673 ↗
37. PD-1/PD-L1 based combinational cancer therapy: icing on the cake10.3389/fphar.2020.00722 ↗
38. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
39. Cisplatin nanoparticles promote intratumoral CD8(+) T cell priming via antigen presentation and t cell receptor crosstalk10.1021/acs.nanolett.2c00478 ↗
40. Bispecific antibody PL-L1 x CD3 boosts the anti-tumor potency of the expanded vgamma2vdelta2 t cells
41. Moving t memory stem cells to the clinic10.1182/blood-2012-11-468660 ↗
42. Polarization diversity of human CD4+ stem cell memory t cells10.1016/j.clim.2015.04.010 ↗
43. Il-12 enhances the natural killer cell cytokine response to ab-coated tumor cells10.1172/JCI0215950 ↗
44. Stepwise regulation of th1 responses in autoimmunity: il-12-related cytokines and their receptors10.1097/01.MIB.0000172808.03877.4d ↗
45. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current tnf-α inhibitors in therapeutics10.3390/ijms22052719 ↗
46. Photodynamic-chemodynamic cascade reactions for efficient drug delivery and enhanced combination therapy10.1002/advs.202002927 ↗